



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 07 Nov 2022 (#42)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

To prepare an application can take 4-18 months, depending on many factors:

1. Mechanism for which you will apply e.g. U54, R01, D43, K43
2. Requirement of preliminary data
3. Time to assemble the research team
4. Time available to work on the grant, taking into consideration other responsibilities
5. Time for internal review

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Important Notices

Gearing Up for Transition to FORMS-H Application Forms: As [announced](#) over the summer, NIH requires the use of updated application forms (FORMS-H) for due dates on or after January 25, 2023. . The [How to Apply – Application Guide](#) was updated on October 25 with FORMS-H application form instructions to prepare for the transition. Also see [Guide Notice NOT-OD-23-012](#). All form changes are listed in [High-level Grant Application Form Change Summary: FORMS-H](#). A key change in FORMS-H is support for the implementation of the 2023 [NIH Data Management and Sharing Policy](#).

The intended due date for your application determines the correct form version to use.

- DO use FORMS-G form version for application due dates on or before January 24, 2023
- DO use FORMS-H form version for application due dates on or after January 25, 2023
- DO NOT use FORMS-H too early or FORMS-G too late

Notices of Special Interest (NOSI)

[NOT-DA-23-012](#) Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R01, R21, R03). The purpose of this Notice is to inform potential applications to the National Institute on Drug Abuse (NIDA) of special interest in grant applications to conduct rigorous health services and economic research to maximize the availability and delivery of efficient, effective drug, alcohol, and tobacco treatment and recovery support services. Examples of such research include: (1) clinical quality improvement; (2) quality improvement in services organization and management; (3) implementation science; (4) availability, demand, access, and financing; (5) effectiveness; and (6) development or improvement of research methodology, analytic approaches, and measurement instrumentation. This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through January 8, 2026. Submit applications for this initiative using one of the funding opportunity announcements (FOAs) listed in the notice or any reissues of these announcement through the expiration date of this notice.

[NOT-DA-24-004](#) Targeting Epigenetic Regulators for Treating Addiction and Substance Use Disorders. The National Institute on Drug Abuse ([NIDA](#)) is issuing this Notice of Special Interest (NOSI) to inform applicants about NIDA's special interest in innovative research that uses chemical and pharmacological approaches to identify and target epigenetic regulators and mechanisms for the treatment of addiction and substance use disorders. This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through January 8, 2026. Submit applications for this initiative using one of the funding opportunity announcements (FOAs) listed in the notice or any reissues of these announcements through the expiration date of this notice.

Funding Opportunity Announcements (FOA)

1. Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PA-23-044](#)

Type: Competitive Revision to Existing NIH Grants and Cooperative Agreements

Application Due Date: dates may vary by awarding IC. See the Urgent Guide Notices for any applicable Application Due Dates.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Funding Opportunity Announcement: The National Institutes of Health (NIH) hereby notify Principal Investigators on specific types of NIH research grants, listed in the Urgent Notice of Special Interest that funds may be available for competitive revisions to meet immediate needs to help address a specific public health crisis in a timely manner, but that were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for Urgent Competitive Revisions will be routed directly to the NIH awarding component listed on the NoA of the most recent parent award. Only applications submitted in response to an Urgent Guide Notice published by an IC will be allowed to apply to this FOA.

Budget: Application budgets are not limited but must reflect the actual needs of the proposed project.

2. Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) (U19 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-23-033](#)

Type: U19

Application Due Date: March 15, 2023; March 15, 2024; March 14, 2025. All applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support translation of advanced HIV-1 vaccine candidates from pre-clinical studies through different phases of process and product development, Current Good Manufacturing Practice (CGMP) manufacturing and regulatory filing to the point of clinical testing. The FOA will support technology transfer, preclinical immunogenicity and optimization studies, process development, analytical assay development, qualification, validation, testing, small scale pilot or engineering runs, CGMP manufacture in partnership with Pharma/Biotech/Contract Manufacturing Organizations (CMO), quality assurance/quality control oversight, fill-finish activities, product release and storage, generation of reference standard, drug substance and drug product stability testing programs, Investigational New Drug (IND)-enabling studies, and regulatory submission preparation.

Budget: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. NIAID intends to commit at least \$4M in FY 2024 to fund 1-2 awards. Future year amounts will depend on annual appropriations. Application budgets are limited to \$3,000,000 direct costs per year for the 1st and 2nd years of award. Application budgets need to reflect the actual needs of the proposed program. The project period is up to five years.

3. Functional Validation and/or Characterization of Genes or Variants Implicated in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-23-041](#)

Type: R21/R33

Application Due Date: March 02, 2023; July 26, 2023; March 04, 2024; July 26, 2024; March 03, 2025; July 28, 2025. All applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Funding Opportunity Announcement: The purpose of this initiative is to support projects that functionally validate and/or characterize genes or variants involved in substance use disorder-relevant phenotypes.

Budget: Application budgets may not exceed \$125,000 per year in direct costs for the R21 phase. Applications may not exceed \$250,000 per year in direct costs for the R33 phase. The R21 phase may not exceed two years, while the R33 phase may not exceed 3 years. The total project period may not exceed 5 years.

4. Targeting Inflammasomes in Substance Abuse and HIV (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DA-24-003](#)

Type: R01

Application Due Date: March 15, 2023. All applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Funding Opportunity Announcement: The goal of this Funding Opportunity Announcement (FOA) is to encourage research to explore mechanisms of inflammasome activation, humoral immune reaction and potential antibody-mediated enhancement, and their link to immune functions in people with HIV and substance use disorders (SUDs). This FOA supports studies to either (1) elucidate the mechanisms of inflammasomes in virus and drug-induced immune activation, or (2) identify molecular markers and CNS immune cells associated with HIV-1 infection or disease progression among individuals with SUD. Success of these projects may lead to development of novel therapies that target inflammasome activation or suppression to treat neuroinflammation and immune dysregulation in people with HIV.

Budget: NIDA intends to support up to 6 awards for RFA-DA-24-003 and RFA-DA-24-004, corresponding to a total of \$ 4,000,000 in FY 2024. Future year amounts will depend on annual appropriations. Application budgets are limited to \$500,000 direct costs per year and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is five years.

5. Targeting Inflammasomes in Substance Abuse and HIV (R21 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DA-24-004](#)

Type: R21

Application Due Date: March 15, 2023. All applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Funding Opportunity Announcement: The scientific objective of this Funding Opportunity Announcement (FOA) is to encourage research to explore mechanisms of inflammasome activation, humoral immune reaction and potential antibody-mediated enhancement, and their link to immune functions in people with HIV and substance use disorders (SUDs). This FOA supports studies to either (1) elucidate the mechanisms of inflammasomes in virus and drug-induced immune activation, or (2) identify molecular markers and CNS immune cells associated with HIV-1 infection or disease progression among individuals with SUD. Success of these projects may lead to development of novel therapies that target inflammasome activation or suppression to treat neuroinflammation and immune dysregulation aroused in these processes.

Budget: NIDA intends to support up to 6 awards for [RFA-DA-24-003](#) and [RFA-DA-24-004](#), corresponding to a total of \$ 4,000,000 in FY 2024. Future year amounts will depend on annual appropriations. The combined budget for direct costs for the two-year project period may not exceed \$275,000, and need to reflect the actual needs of the proposed project.

6. Building Research Capacity in Global Tobacco Product Regulation Program (U18) Clinical Trials Not Allowed

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-FD-23-003](#)

Type: U18

Application Due Date: January 16, 2023 by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date.

Funding Opportunity Announcement: The Food and Drug Administration (FDA) announces its intention to accept and consider a single source application for award to the World Health Organization (WHO) for the Building Research Capacity in Global Tobacco Product Regulation Program. The purpose of the Program is to identify, support, develop, conduct, and coordinate research efforts relating to tobacco control laws and rules in foreign countries that will directly inform and support FDA's exercise of its authority to regulate the manufacture, distribution, marketing and sale of tobacco products in the United States. The Program will advance FDA's Center for Tobacco Products' (CTP's) mission by utilizing WHO Member States' expertise and extensive international contacts in global tobacco control, as well as WHO's own programmatic expertise, to inform and support adequate manufacture, distribution and market regulations of tobacco products for the protection of public health in the United States. The Program will also provide a universal public benefit by creating opportunities for collaboration and research development globally, thereby resulting in better-informed and effective tobacco product regulation around the world, and increased knowledge in the public sphere regarding tobacco use and its harms globally.

Budget: The number of awards is contingent upon FDA appropriations and the submission of a sufficient number of meritorious applications. Award(s) will provide one (1) year of support and include future recommended support for four (4) additional year(s) contingent upon annual appropriations, availability of funding and satisfactory recipient performance. FDA/CTP intends to commit up to \$400,000 in FY 2023 to fund one award in support of this cooperative agreement program (total costs including indirect costs for one award subject to availability of funds).

7. HEAL Initiative Integrated Basic and Clinical Team-based Research in Pain (RM1 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-NS-22-069](#)

Type: RM1

Application Due Date: February 14, 2023; June 14, 2023; October 13, 2023; February 12, 2024

Funding Opportunity Announcement: This funding opportunity announcement (FOA) is designed to support integrated efforts of three or more (up to six) PDs/PIs to pursue bold, impactful, and challenging research in basic and clinical pain domains to understand the biology of specific human pain conditions as well as pain associated with various diseases/disorders, including mechanistic underpinning of heterogeneity and stratification of patients with specific pain conditions and co-morbidities. The research approach should be interdisciplinary in nature, and the research teams are expected to establish a common goal that requires collaboration, synergy, and managed team interactions. Proposed research should not represent a collection of individual efforts or parallel projects. Proposed research should support a cohesive, single, well-integrated research plan with a singular focus, one set of aims, and a budget without subprojects. Teams must leverage appropriate multi-disciplinary expertise to develop new principles and methods for experimentation, analysis, and interpretation. Teams are encouraged to consider transformative objectives with defined 5-year outcomes that will produce major advances in the understanding of human pain conditions and are likely to improve strategies for effective management of human pain.

Budget: NIH intends to fund an estimate of 3-4 awards for fiscal year 2023. Future year amounts will depend on annual appropriations. Application budgets should not exceed \$1,000,000 direct costs per year, and should be consistent with the number of PDs/PIs and the complexity and needs of the proposed program. Annual inflationary increases are not allowed. Applications may request up to five years of support.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences
Kth Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Division for Research Development (DRD)
Stellenbosch Campus
2041 Krotoa Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105